Gefapixant Medicine 08 December 2020 Extended indication Adult Participants With unexplained Chronic Cough Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Gefapixant Domain Lung diseases Reason of inclusion New medicine (specialité) Main indication Lung other Extended indication Adult Participants With unexplained Chronic Cough Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer MSD Portfolio holder Mechanism of action Receptor antagonist Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date 2021 Expected Registration 2022 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Datum indiening en verwachte registratie is op basis van estimated primary completion June 2020. Therapeutic value Current treatment options hoestprikkeldempende middelen (codeïne) Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 2 times a day Dosage per administration 45mg tot 50mg References NCT03449134 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Morice A. Chronic cough: epidemiology. Chron Respir Dis. 2008;5(1):43-7. Additional remarks Onder chronisch hoesten wordt verstaan dat het hoesten meer dan 8 weken aanhoudt. De prevalentie in de algemene bevolking wordt geschat op 12%. De drie voornaamste oorzaken van chronisch hoesten bij een niet-roker met een normale thoraxradiografie zijn astma, gastro-intestinale reflux (GER) en rhinosinusitis. Voor een aanzienlijk aantal patiënten kan er echter geen oorzaak gevonden worden en is er sprake van chronische idiopatische hoest. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks